Clinical efficacy and safety of Dapagliflozin combined with sacubitril valsartan in the treatment of heart failure patients with reduced ejection fraction
Objective To investigate the clinical efficacy and safety of Dapagliflozin combined with sacubitril valsartan in the treatment of heart failure patients with reduced ejection fraction.Methods A total of 86 heart failure patients with reduced ejection fraction admitted to Zhengzhou Seventh People's Hospital from January 2020 to June 2021 were selected as the study objects and were divided into two groups according to the envelope randomization method.In the experimental group,the ratio of male to female was 26/17,and the age was(65.08±5.52)years old.In the control group,the ratio of male to female was 27/16,and the age was(65.21±5.37)years old.Forty-three patients in the control group were treated with sacubitril valsartan,and 43 patients in the experimental group were treated with Dapagliflozin on this basis,continuous oral administration for 3 months.The therapeutic effect,cardiac function,6-min walking distance(6MWD),N-terminal brain natriuretic peptide precursor(NT-proBNP),and inflammatory factors were compared between the two groups.t test and x2 test were used.Results After 3 months of administration,the total effective rate of the heart failure patients with reduced ejection fraction in the experimental group was higher than that in the control group[95.35％(41/43)vs.79.07％(34/43)],with a statistically significant difference(P＜0.05).After 3 months of administration,the levels of left ventricular end-diastolic inner diameter(LVIDd),NT-proBNP,interleukin-6(IL-6),C-reactive protein(CRP),and tumor necrosis factor α(TNF-α)in both groups were decreased compared with those before administration,and those in the experimental group were lower than those in the control group;the left ventricular ejection fraction(LVEF)and 6MWD levels in both groups were significantly increased compared with those before administration,and those in the experimental group were higher than those in the control group,with statistically significant differences(all P＜0.05).There was no statistically significant difference in the incidence of adverse reactions between the experimental group and the control group[13.95％(6/43)vs.11.63％(5/43)](P＞0.05).Conclusion In the treatment of heart failure patients with reduced ejection fraction,Dapagliflozin combined with sacubitril valsartan has significant efficacy,which can reduce the inflammation,improve the cardiac function,increase the cardiac ejection fraction,and is safe and worthy of application.
万方数据
维普
